Literature DB >> 7929131

Carboxyl-terminal truncation of recombinant factor XIII A-chains. Characterization of minimum structural requirement for transglutaminase activity.

T S Lai1, K E Achyuthan, M A Santiago, G S Greenberg.   

Abstract

A series of truncation mutants lacking 218, 229, 250, and 269 amino acid residues from the carboxyl terminus of blood coagulation factor XIII A-chains (FXIII A), designated as delta K513, delta A502, delta Y481, and delta K462, respectively, were expressed in Escherichia coli to define the minimum structure required for transglutaminase activity. delta K513 and delta A502 displayed a 3.8-4.7-fold reduction in the Kcat with no change in the Km for the glutamine substrate and a 2-fold increase in the Km of the primary amine substrate. There was no detectable transglutaminase activity for either thrombin-activated delta Y481 or delta K462. The rate of ammonia release of thrombin-activated delta K513 and delta A502 was reduced 6- and 4-fold, respectively, whereas ammonia release was not detected for the delta Y481 and delta 462 mutants. The Kact for calcium ions of the delta K513 mutant was similar to recombinant FXIIIa, whereas, it was increased by approximately 3-fold for the delta A502 mutant. The rate of fibrin gamma-chain dimer formation for the delta K513 and delta A502 mutants was reduced by approximately 19-fold. delta K462 did not bind to fibrin, while all of the other thrombin-cleaved mutants were bound. In conclusion, these results documented that the carboxyl-terminal calcium binding domain (Asp468-Glu495) was important for FXIIIa to adopt the correct conformation to ensure that efficient catalysis occurred.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7929131

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  5 in total

1.  Identification of chemical inhibitors to human tissue transglutaminase by screening existing drug libraries.

Authors:  Thung-S Lai; Yusha Liu; Tim Tucker; Kurt R Daniel; David C Sane; Eric Toone; James R Burke; Warren J Strittmatter; Charles S Greenberg
Journal:  Chem Biol       Date:  2008-09-22

2.  Discovery of potent and specific dihydroisoxazole inhibitors of human transglutaminase 2.

Authors:  Cornelius Klöck; Zachary Herrera; Megan Albertelli; Chaitan Khosla
Journal:  J Med Chem       Date:  2014-10-31       Impact factor: 7.446

3.  Role of calcium in the conformational dynamics of factor XIII activation examined by hydrogen-deuterium exchange coupled with MALDI-TOF MS.

Authors:  Ricky T Woofter; Muriel C Maurer
Journal:  Arch Biochem Biophys       Date:  2011-05-26       Impact factor: 4.013

4.  Characterization of the reciprocal binding sites on human alpha-thrombin and factor XIII A-chain.

Authors:  K E Achyuthan
Journal:  Mol Cell Biochem       Date:  1998-01       Impact factor: 3.396

5.  The role of β-barrels 1 and 2 in the enzymatic activity of factor XIII A-subunit.

Authors:  E L Hethershaw; P J Adamson; K A Smith; W N Goldsberry; R J Pease; S E Radford; P J Grant; R A S Ariëns; M C Maurer; H Philippou
Journal:  J Thromb Haemost       Date:  2018-05-27       Impact factor: 5.824

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.